Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study

The Qatar Study was designed to examine the efficacy of combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea. The study randomized 231 patients with poorly controlled (HbA >7.5%, 58 mmol/mol) T2DM on a sulfonylurea plus metformin to receive ) pioglitazone plus weekly exenatide (combination therapy) or ) basal plus prandial insulin (insulin therapy) to maintain HbA